The National Lipid Association and PlatformQ Health Partner on CME Series Aimed at Reducing CVD Risk

Michael J. Blaha, MD, MPH
Preventive Cardiology

John Hopkins University

The lipid-lowering field is evolving at an ever-accelerating rate. With new studies at nearly every major meeting, clinicians need succinct summaries of the latest evidence and how to apply it in their practice.

High cholesterol — particularly a high level of low-density lipoprotein cholesterol (LDL-C) — is a main risk factor for developing cardiovascular disease (CVD), the number one cause of death in the United States. Treatment with statins has been shown to effectively lower LDL-C, but not for everyone. About 70% of patients with elevated LDL-C levels go untreated due to statin resistance, statin intolerance, familial hypercholesterolemia not well controlled on statins and nonadherence to statin treatment. For these patients, a newer class of injectable drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, represents one of the most promising strategies.

To help educate clinicians on PCSK9 inhibitors and CVD risk reduction, the National Lipid Association and PlatformQ Health are partnering to produce a two-part online series airing on

Part 1 – The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction

Live: Tuesday, April 11, 2017 2:00 PM – 3:00 PM EST

Part 2 – CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications

Live: Tuesday, May 23, 2017 11:00 AM – 12:00 PM EST

CME credit provided by the National Lipid Association.

These activities have been approved for AMA PRA CATEGORY 1 CREDIT™.

These activities are eligible for ACPE and ANCC credit.

Clinicians can Register Here for the Series


  • Michael J. Blaha, MD, MPH; Director of Clinical Research,…

Read the full article at the Original Source..

Back to Top